Search Result

Results for "

SOS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SOS1 (69) Apoptosis (3) Bacterial (7) Biochemical Assay Reagents (1) Cytochrome P450 (1) DNA/RNA Synthesis (3) Drug Derivative (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (3) EGFR (2) Environmental Pollutants (1) ERK (8) Ferroptosis (2) HDAC (1) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (5) MEK (2) Molecular Glues (2) Nucleoside Antimetabolite/Analog (1) p38 MAPK (2) PERK (4) Potassium Channel (1) PROTAC Linkers (2) PROTACs (16) Ras (71) Reference Standards (2) SHP2 (1) Small Interfering RNA (siRNA) (7) Target Protein Ligand-Linker Conjugates (1)
By Research Areas:	Cancer (91) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Nucleotide Analogs (1) Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) Antisense Oligonucleotides (1) siRNAs (7)

114

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: SOS1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145928

Divarasib 5+ Cited Publications GDC-6036	Ras	Cancer
Divarasib (GDC-6036) is an orally active, selective KRAS ^G12C inhibitor with an IC₅₀ of <0.01 μM. Divarasib covalently binds Cys12 in GDP-bound KRAS ^G12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRAS ^G12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRAS ^G12C-mutated solid tumors .

HY-114398

BAY-293 2 Publications Verification	SOS1 Ras	Cancer
BAY-293, a valuable chemical probe, blocks RAS activation via disruption of the *KRAS-SOS1* interaction with an IC₅₀ of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS .

HY-145926

MRTX0902 2 Publications Verification	SOS1 Ras	Neurological Disease Cancer
MRTX0902 is a potent, selective, brain-penetrant, and orally active *SOS1* inhibitor with a K_i of 1.9 nM. MRTX0902 disrupts the SOS1:KRASG12C protein-protein interaction (PPI). MRTX0902 can be used in research on pancreatic ductal adenocarcinoma .

HY-151881

SOS1-IN-15	SOS1 Ras	Cancer
SOS1-IN-15 (Compound 37) is an orally active *SOS1* inhibitor with an IC₅₀ of 5 nM. SOS1-IN-15 is a promising agent candidate for the research of KRAS-driven cancer .

HY-111671

VUBI1 SOS1 activator 1	SOS1 Ras PERK Ligands for Target Protein for PROTAC	Cancer
VUBI1 (SOS1 activator 1) is a benzimidazole derivative and *SOS1* activator with a K_d of 44 nM. VUBI1 can significantly activate RAS-GTP and regulate the phosphorylation of ERK. VUBI1 also can serve as a target ligand for synthesizing PROTACs, such as PROTAC SOS1 degrader-1 (HY-145737), to induce SOS1 degradation. VUBI1 can be used in the study of cancer .

HY-18674

K-Ras-IN-1	Ras	Cancer
K-Ras-IN-1 is the inhibitor for K-Ras by occupying the binding site of son of sevenless (Sos), preventing the interaction between Sos and K-Ras, inhibiting the Sos-catalyzed GDP to GTP exchange process. K-Ras-IN-1 is promising for research of pancreatic, colon and lung cancer .

HY-134885

RMC-0331 1 Publications Verification RM-023	SHP2 SOS1 Ras	Cancer
RMC-0331 (RM-023) is a potent, selective and orally bioavailable *SOS1* inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction .

HY-114398A

(S)-BAY-293	Ras SOS1	Others
(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor .

HY-P2265A

*SAH-SOS1A TFA*	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-145737A

*PROTAC SOS1 degrader-1 TFA*	PROTACs Ras	Cancer
PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-W096997A

*Sodium octyl sulfate (SOS), 95%* Sodium capryl sulfate, 95%	Biochemical Assay Reagents	Others
Sodium octyl sulfate (SOS), 95% (Sodium capryl sulfate, 95%) is an anionic detergent and ion-pairing agent.

HY-153606

VUBI1 analogue-1	Drug Derivative HDAC	Cancer
VUBI1 analogue-1 (compound 79) is a VUBI1 (HY-111671) analogue. VUBI1 (SOS1 activator 1) is a SOS1 activator with a K_d of 44 nM. VUBI1 analogue-1 can be used to synthesize (4S)-PROTAC SOS1 degrader-1 (HY-144657) ^{[1] ^.}

HY-163939

RGT-018	SOS1 Ras	Cancer
RGT-018 is a potent and orally active *SOS1* inhibitor with anti-tumor effects. RGT-018 exerts anti-cancer cell proliferation activity by inhibiting KRAS activation .

HY-132966

ASP2453 1 Publications Verification	Ras ERK	Cancer
ASP2453 is a potent, selective and orally active KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC₅₀ value of 40 nM.

HY-148261

KRAS G12C inhibitor 56	Ras	Cancer
KRAS G12C inhibitor 56 (compound IC-6) is a potent *SOS1* inhibitor with an IC₅₀ of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research .

HY-161235

BTX-7312	SOS1 Molecular Glues Ras	Cancer
BTX-7312 is a cereblon-based *SOS1* bifunctional degrader and a molecular glue. BTX-7312 reduces downstream signaling markers pERK and pS6 and shows antiproliferative activity in various KRAS-mutated cells .

HY-179443

SOS1-IN-25	SOS1 Ras	Cancer
SOS1-IN-25 is an *SOS1* inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRAS ^G12C/SOS1 complex formation (IC₅₀ = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia .

HY-151517

SOS1-IN-14	SOS1 Ras	Cancer
SOS1-IN-14 is a potent, selective and orally active *SOS1* inhibitor with an IC₅₀ value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817) .

HY-W056267

3-Boc-3-azaspiro[5.5]undecane-9-carbaldehyde	PROTAC Linkers	Cancer
3-Boc-3-azaspiro[5.5]undecane-9-carbaldehyde is a PROTAC linker, and can be used for synthesis of PROTAC SOS1 degrader-8 (HY-161634) .

HY-161233A

BTX-6654 formate	PROTACs SOS1 ERK	Cancer
BTX-6654 formate is a target-dependent and -specific cereblon-based bifunctional SOS1 PROTAC degrader. BTX-6654 formate reduces downstream signaling markers pERK and pS6, and displays antiproliferative activity in cells harboring various KRAS mutations .

HY-175560

SOS1-IN-22	SOS1 PERK	Cancer
SOS1-IN-22 is a son of sevenless homolog 1 (SOS1) inhibitor. SOS1-IN-22 can inhibit KRAS-G12C/SOS1 complex formation with an IC₅₀ value of 40.28 nM. SOS1-IN-22 can reduce phosphorylation ERK levels. SOS1-IN-22 can be used for the research of cancer, such as pancreatic carcinoma and appendiceal carcinoma .

HY-176170

SOS1-IN-19	SOS1	Cancer
SOS1-IN-19 (Compound 10i) is a potent inhibitor of *SOS1* (Son of Sevenless 1) with an IC₅₀ value of 165.2 nM. SOS1-IN-19 blocks KRAS activation by preventing GDP/GTP exchange in KRAS signaling pathway. SOS1-IN-19 is promising for research of KRAS-driven cancers (e.g., NSCLC and colorectal cancer) .

HY-152145

*PROTAC SOS1 degrader-3*	SOS1 PROTACs Ras	Cancer
PROTAC SOS1 degrader-3 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-3 effectively targeted SOS1 for degradation through the ubiquitin-proteasome system .

HY-167768

SOS1 activator 2	SOS1 ERK Ras	Cancer
SOS1 activator 2 (Compound 65) is a benzimidazole derivative and a *SOS1* activator. SOS1 activator 2 has a high binding affinity for *SOS1* with a K_d of 9 nM. SOS1 activator 2 can regulate the Ras-ERK signaling pathway, which can be used in the study of cancer .

HY-145737

*PROTAC SOS1 degrader-1*	PROTACs Ras	Cancer
PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-P2265

*SAH-SOS1A*	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-144657A

*(4S)-PROTAC SOS1 degrader-1 diTFA*	PROTACs Ras	Cancer
(4S)-PROTAC SOS1 degrader-1 (diTFA) is a potent PROTAC SOS1 degrader. (4S)-PROTAC SOS1 degrader-1 (diTFA) decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. (4S)-PROTAC SOS1 degrader-1 (diTFA) significantly inhibits the tumor growth in vivo .

HY-124514

UC-857993	SOS1 Ras ERK	Cancer
UC-857993 is a selective *SOS1-Ras* inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits ERK and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .

HY-161233

BTX-6654	PROTACs SOS1 ERK	Cancer
BTX-6654 is a target-dependent and -specific cereblon-based bifunctional *SOS1* PROTAC degrader. BTX-6654 reduces downstream signaling markers pERK and pS6, and displays antiproliferative activity in cells harboring various KRAS mutations .

HY-112078B

(S,S,S)-AHPC-Me	Ligands for E3 Ligase	Others
(S,S,S)-AHPC-Me is an E3 ligase ligand. (S,S,S)-AHPC-Me can be used for synthesis of PROTAC (4S)-PROTAC SOS1 degrader-1 diTFA (HY-144657A) .

HY-178044

SOS1-IN-24	SOS1	Cancer
SOS1-IN-24 (Compound 15) is a *SOS1* inhibitor with an IC₅₀ of 0.398  μM. SOS1-IN-24 effectively disrupts SOS1::KRAS12D interaction. SOS1-IN-24 can be used for cancers like pancreatic and colorectal cancer research .

HY-144212

SOS1-IN-8	SOS1 Ras	Cancer
SOS1-IN-8 is a potent *SOS1* inhibitor with IC₅₀s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2) .

HY-144210

SOS1-IN-6	SOS1 Ras	Cancer
SOS1-IN-6 (compound 33-P1) is a potent *SOS1* inhibitor with IC₅₀s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively .

HY-175244

SOS1-IN-20	SOS1 Ras Potassium Channel	Cancer
SOS1-IN-20 (Compound 12f) is an orally active *SOS1* inhibitor with an IC₅₀ of 5.11 nM against KRAS ^G12C::SOS1. By disrupting the interaction between KRAS and *SOS1, SOS1-IN-20 inhibits KRAS* activation and downstream signal transduction. SOS1-IN-20 has an IC₅₀ of 253 nM for p-ERK in PC-9 cells and 16.71 μM for hERG channel . SOS1-IN-20 can inhibit the proliferation of tumor cells and has antitumor activity .

HY-153940

SOS1/KRAS-IN-1	SOS1 Ras	Cancer
SOS1/KRAS-IN-1(Compound 2) is a *SOS1/KRAS* inhibitor, which can be used in the research of SOS1/KRAS-mediated diseases .

HY-153674

*PROTAC SOS1 degrader-4*	SOS1 PROTACs Ras	Cancer
PROTAC SOS1 degrader-4 (compound 10) is a potent *SOS1* degrader. PROTAC SOS1 degrader-4 shows antiproliferative activity .

HY-163582

*PROTAC SOS1 degrader-7*	PROTACs SOS1 Ras	Cancer
PROTAC SOS1 degrader-7 (Example 15) is a SOS1 PROTAC degrader. PROTAC SOS1 degrader-7 has anti-tumor activity . (Pink: SOS1 ligand (HY-163583); Black: linker (HY-163584); Blue: E3 ligase ligand (HY-W454906)) .

HY-161654

*PROTAC SOS1 degrader-10*	SOS1 PROTACs Ras	Cancer
PROTAC SOS1 degrader-10 (Compound 11o) is a degrader for son of sevenless 1 (SOS1) in a CRBN and proteasome dependent manner. PROTAC SOS1 degrader-10 degrades SOS1 in KRAS mutant cancer cells SW620, A549 and DLD-1, with DC₅₀s of 2.23, 1.85 and 7.53 nM, respectively. PROTAC SOS1 degrader-10 inhibits the proliferations of cells SW620, A549 and DLD-1, with IC₅₀s of 36.7, 52.2 and 107 nM, respectively. PROTAC SOS1 degrader-10 inhibits phosphorylation of ERK. (Pink: SOS1 ligand (HY-161655); Black: linker (HY-161656); Blue: E3 ligase ligand (HY-W249500))

HY-144657

*(4S)-PROTAC SOS1 degrader-1*	PROTACs Ras	Cancer
(4S)-PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader. (4S)-PROTAC SOS1 degrader-1 decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. (4S)-PROTAC SOS1 degrader-1 significantly inhibits the tumor growth in vivo .

HY-168637

SIAIS562055	SOS1 PROTACs Ras	Cancer
SIAIS562055 is a potent cereblon-based SOS1 PROTAC with a K_d of 95.9 nM. SIAIS562055 exhibits sustained degradation of SOS1 and inhibition of downstream ERK pathways. SIAIS562055 effectively blocked the binding of KRAS ^G12C or KRAS ^G12D to SOS1, with the IC₅₀ values of 95.7 nM and 134.5 nM, respectively. SIAIS562055 exhibits potent anticancer activity. (Pink: SOS1 ligand (HY-168638); Black: linker (HY-W539874); Blue: E3 ligase ligand (HY-W076696)) .

HY-161236

KRAS ligand 4	Molecular Glues SOS1 Ras	Cancer
KRAS ligand 4 (compound 2) is a bifunctional molecular glue degrader based on *SOS1*. KRAS ligand 4 reduces downstream signaling markers pERK and pS6 and displays anti-additional activity in cells with multiple KRAS mutations .

HY-134813A

MRTX1133 formic	Ras	Cancer
MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .

HY-W087019

ACDQ 4-Amino-2-chloro-6,7-dimethoxyquinazoline	DNA/RNA Synthesis	Others
ACDQ (4-Amino-2-chloro-6,7-dimethoxyquinazoline) is an inducer of adenylated nucleotide accumulation and also induces heat shock (htpr-controlled), oxidative stress (oxyr-controlled), and SOS (lexa-controlled)-regulated protein synthesis .

HY-145048

SOS1-IN-5	SOS1 Ras	Cancer
SOS1-IN-5 is a potent inhibitor of *SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS*1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4) .

HY-144965

SOS1-IN-12	SOS1 Ras	Cancer
SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a K_i of 0.11 nM for SOS1 and an IC₅₀ of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer .

HY-132129

SOS1-IN-2	Ras SOS1	Cancer
SOS1-IN-2 (Compound 1-1) is an inhibitor of *SOS1* with an IC₅₀ value of 5 nM. SOS1-IN-2 can be used in tumor research .

HY-144211

SOS1-IN-7	SOS1 Ras	Cancer
SOS1-IN-7 (compound 18-p1) is a potent *SOS1* inhibitor with IC₅₀s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively .

HY-144967

SOS1-IN-13	SOS1 Ras	Cancer
SOS1-IN-13 is a potent son of sevenless homolog 1 (SOS1) inhibitor with IC₅₀s of 6.5 nM and 327 nM for SOS1 and pERK, respectively. SOS1-IN-13 can be used for researching anticancer .

HY-144207

SOS1-IN-9	SOS1 Ras	Cancer
SOS1-IN-9 is a potent *SOS1* inhibitor with an IC₅₀ of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302) .

HY-153989

SOS1-IN-16	Ras Cytochrome P450 SOS1	Cancer
SOS1-IN-16 (Comp 54) is a selective inhibitor of *SOS1* with an IC₅₀ of 7.2 nM. SOS1-IN-16 has inhibitory activity of CYP3A4 when using testosterone as a substrate, with an IC₅₀ of 8.9μM. SOS1-IN-16 can be used for cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P2265A

*SAH-SOS1A TFA*	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P2265

*SAH-SOS1A*	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-138616

dGTP 2'-Deoxyguanosine-5'-triphosphate	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog
dGTP (2'-Deoxyguanosine-5'-triphosphate) is one of the precursors for DNA synthesis, and serves as a direct substrate for DNA replication and repair. dGTP is prone to oxidative damage; under the action of reactive oxygen species and other factors, dGTP is oxidized to form 8-oxo-dGTP .

HY-N9110

7,3′,4′-Tri-O-methyleriodictyol	Flavonoids Monophenols Classification of Application Fields Entada phaseoloides (L.) Merr. Flavones Labiatae Other Diseases Phenols Plants Disease Research Fields Source Classification	Others
7,3′,4′-Tri-O-methyleriodictyol is a flavonoid with an antimutagenic activity. 7,3′,4′-Tri-O-methyleriodictyol inhibits the furylfuramide-induced SOS response and has potency as bioantimutagens .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704193

	SOS1 Protein, Human (Active, sf9, His) GF1 Protein, Human; GGF1 Protein, Human; GINGF Protein, Human; HGF Protein, Human; NS4 Protein, Human; SOS-1 Protein, Human	Human	Sf9 insect cells
	SOS1 Protein, Human (Active, sf9, His) is the recombinant human-derived SOS1 protein, expressed by Sf9 insect cells, with N-His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W096997S

Sodium octyl sulfate (SOS)-d17

Sodium octyl sulfate (SOS)-d₁₇ (Sodium capryl sulfate-d₁₇) is the deuterated analogue of Sodium octyl sulfate (SOS). Sodium octyl sulfate (Sodium capryl sulfate; SOS) is a medium‑chain anionic surfactant. Sodium octyl sulfate (SOS) can undergo strong hydrophobic interactions with serum albumins (such as human serum albumin (HSA) and bovine serum albumin (BSA)), while exhibiting weak interactions with other proteins including myoglobin and hemoglobin. As an environmental pollutant in freshwater ecosystems, Sodium octyl sulfate (SOS) can mimic interspecific pheromones released by Daphnia magna and induce the formation of multicellular colonies in green algae.

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83568

	SOS1 Antibody (YA3313) alternate SOS1; GF1; GGF1; GINGF; gingival fibromatosis; HGF; NS4; SOS1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	SOS1 Antibody (YA3313) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SOS1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-134813

MRTX1133 45+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

Cat. No.	Product Name		Classification

HY-108746

Defibrotide sodium		Antisense Oligonucleotides
Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. Defibrotide sodium can be used for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) research .

HY-138616

dGTP 2'-Deoxyguanosine-5'-triphosphate		Nucleotide Analogs
dGTP (2'-Deoxyguanosine-5'-triphosphate) is one of the precursors for DNA synthesis, and serves as a direct substrate for DNA replication and repair. dGTP is prone to oxidative damage; under the action of reactive oxygen species and other factors, dGTP is oxidized to form 8-oxo-dGTP .

HY-RS26460

Sos2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Sos2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sos2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS13576

SOS1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SOS1 Human Pre-designed siRNA Set A contains three designed siRNAs for SOS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS23001

Sos1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Sos1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sos1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS19958

Sos2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Sos2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sos2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS13577

SOS2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SOS2 Human Pre-designed siRNA Set A contains three designed siRNAs for SOS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16568

Sos1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Sos1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sos1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15908

XYLT2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
XYLT2 Human Pre-designed siRNA Set A contains three designed siRNAs for XYLT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks